Navigation Links
Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic
Date:9/9/2009

SAN DIEGO, Sept. 9 /PRNewswire/ -- aTyr Pharma announced today that the US Patent office has issued patent US 7,572,452 B2, titled "Method for Stimulating Wound Healing." aTyr Pharma is the sole assignee of this patent, and Professor Sunghoon Kim, a scientific co-founder of aTyr Pharma, is the inventor. An example of aTyr Pharma's broad intellectual property portfolio and the fifteenth filed patent related to aTyr Pharma's work in tRNA synthetases, this patent covers new extracellular activities for p43, a critical protein component of the multi-aminoacyl tRNA synthetase complex in humans. The aminoacyl tRNA synthetases are universal and essential elements of the protein synthesis machinery found in all organisms, but human synthetases and their associated proteins have naturally occurring resected variants, called "resectins," with potent cell signaling activities that are vital to normal functioning of humans. The resectins' activities are distinct from the protein synthesis activities commonly known for synthetases, and aTyr Pharma is discovering and developing the resectins as new biotherapeutic agents that can be used to treat a wide variety of human diseases including inflammatory, autoimmune, hematopoietic and metabolic disorders.

Jeff Watkins, CEO of aTyr Pharma, had this to say about the patent: "This patent covers discoveries Professor Kim has made for extracellular activity of the p43 component of the multi-sythetase complex. As part of aTyr Pharma's portfolio, this patent helps establish our dominant ownership and leadership in the resectin space. Capitalizing on this new area of biology, we are identifying and developing these naturally occurring resectins as candidate biotherapeutics for treating a wide variety of diseases."

Professor Kim, of Seoul National University in Korea, has had a long scientific relationship with Professor Paul Schimmel of The Scripps Research Institute and a co-founder of aTyr Pharma. According to Professor Schimmel, "Professor Kim's research has really helped build our understanding of how far-reaching the non-canonical functions are for naturally occurring resectins of tRNA synthetases and their associated proteins. This newly issued patent highlights the innovation surrounding the discovery and development of tRNA synthetase resectins as biotherapeutics." Professors Schimmel and Kim recently co-authored a scientific article in the Proceedings of the Natural Academy of Sciences (PNAS USA, 2008, vol. 105: 11043-11409) describing many of the newly emerging functions of tRNA synthetases and the relationships to human medicine.

Link to the PNAS review article: http://www.pnas.org/content/105/32/11043.full.pdf

About aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on the discovery and development of an entirely new class of biologics. aTyr Pharma's discovery engine for new biotherapeutics consists of novel proteins in the family of tRNA synthetases with cell signaling activities distinct from the protein synthesis activities commonly associated with the tRNA synthetases. These resected proteins, or "resectins," are being developed as novel therapeutics to treat hematological disorders, neurodegenerative diseases, inflammation, cardiovascular diseases and metabolic disorders.

www.atyrpharma.com


'/>"/>
SOURCE aTyr Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fifteenth Annual Pridelights Goes Green
2. Genova files patent for new prostate cancer treatment
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
4. TANCS Steam Vapor Granted U.S. Patent
5. Milestone Scientific Announces Notice of Allowance From US Patent and Trademark Office
6. Palomar Successful in U.S. Patent Office Re-Examination of Second Hair Removal Patent
7. Secure eHealth Partner Receives Patent and Notice of Patent Allowance that is Key to Enriched Data Portability in Healthcare
8. U.S. District Court Rules Against Lilly Regarding Gemzar Patent
9. Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office
10. German District Court Rules in Smith & Nephews Favor in Patent Infringement Case
11. AlphaRx Receives China Patent on Its Drug Delivery Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... 2017 , ... Maryland’s soybean farmers have improved the sustainability ... the United Soybean Board. , Thanks to the responsible use of technology ... on less land per bushel, the report says. The United Soybean Board’s “Soy ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with missing ... Cotey, with or without a referral. Dr. Cotey is a trusted dentist who has ... tooth replacement option. , Patients with missing teeth in Fitchburg, WI, are encouraged to ...
(Date:6/25/2017)... ... ... CareSet Labs released the Root NPI Graph today at the 2017 Academy ... of the Doctor Referral teaming dataset commonly available from Medicare. , Originally created through ... “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released by Trotter, the ...
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. Mitchell Mehlman ... Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine and emergency ... the dentist fit into their patients’ busy lifestyles. Dental365 also gladly work with ...
(Date:6/23/2017)... ... ... By scoring 100% for fiscal management and accountability, the Arthritis National Research ... Charity Navigator, validating ANRF's work as a top charity in America. , This achievement ... earns ANRF a spot on their “ 10 Charities Worth Watching ” list as ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... CHICAGO , June 19, 2017  Hill-Rom Holdings, Inc. ... conference call and webcast on Friday, July 28, 2017, beginning ... Conference Call Audio Only Dial-in information: To participate in the ... Please dial into the call at least 10 minutes prior ... Code is 34090339.  ...
(Date:6/16/2017)... -- Datascope Corp. is voluntarily performing a worldwide field correction of certain Intra-Aortic ... code.     ... NUMBER ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX ... This field correction also applies to any System ...
(Date:6/14/2017)... , June 14, 2017  ivWatch LLC, a medical ... of intravenous (IV) therapy, is pleased to announce it ... of Nonsurgical Hospital Supplies and Equipment at the 2017 ... for the medtech industry. The award was presented by ... K. Javits Center in New York ...
Breaking Medicine Technology: